查看購物車
  • English
  • Japanese
罕見疾病基因檢測市場規模、佔有率和成長分析：按檢測類型、疾病類別、最終用戶、通路和地區分類－2026-2033年產業預測
市場調查報告書
商品編碼
2048662

罕見疾病基因檢測市場規模、佔有率和成長分析：按檢測類型、疾病類別、最終用戶、通路和地區分類－2026-2033年產業預測

Rare Disease Genetic Testing Market Size, Share, and Growth Analysis, By Test Type (Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS)), By Disease Category, By End-User, By Distribution, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2024 年全球罕見疾病基因檢測市值為 45.2 億美元，預計到 2025 年將成長至 50.8 億美元，到 2033 年將成長至 128.5 億美元，在預測期（2026-2033 年）內複合年成長率為 12.32%。

全球罕見疾病基因檢測市場正受到次世代定序技術日益普及和人們對早期疾病診斷重要性認知不斷提高的推動。政府主導的各項措施、精準醫療的發展以及人們對個人化醫療日益成長的需求，也是推動這一市場需求的關鍵因素。此外，基因組和新生兒篩檢篩檢的擴展，以及對先進定定序技術和生物資訊學的持續投入，正在提升識別和解讀基因突變的能力。然而，高昂的檢測成本、訓練有素的遺傳諮詢師短缺、資料隱私方面的倫理困境以及不一致的報銷政策等挑戰，可能會阻礙罕見疾病基因檢測市場的長期成長。

全球罕見疾病基因檢測市場按檢測類型、疾病類別、最終用戶、分銷管道和地區進行細分。按檢測類型分類，市場細分包括全EXOME序 (WES)、全基因組定序 (WGS)、基因panel檢測和染色體微陣列分析。依疾病類別分類，市場細分包括代謝性疾病、神經肌肉疾病、染色體異常和結締組織疾病。按最終用戶分類，市場細分包括醫院、參考實驗室和研究機構。按分銷方式分類，市場細分為直接面向醫生 (DTP) 和直接面對消費者 (DTC)。按地區分類，市場細分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球罕見疾病基因檢測市場的成長要素

全球罕見疾病基因檢測市場的主要促進因素之一是罕見遺傳疾病的盛行率和認知度不斷提高。隨著越來越多的人被診斷出患有這些疾病，對準確且高效的檢測方法的需求也日益成長。基因技術的進步以及研發的不斷深入，正推動著創新檢測方案的開發，從而實現早期發現和個人化治療方案的發展。此外，政府和醫療機構為提高罕見疾病診斷能力而推出的支持政策和舉措，也促進了市場成長，並確保患者能夠及時有效地應對其獨特的遺傳挑戰。

全球罕見疾病基因檢測市場的限制因素

影響全球罕見疾病基因檢測市場的主要限制因素之一是基因檢測流程及後續分析的高成本。許多先進的基因檢測費用高昂，令患者和醫療系統難以承受，這限制了他們獲得這些關鍵診斷的機會。此外，遺傳物質的複雜性以及對專業檢查室的需求也會造成額外的經濟負擔。這種經濟障礙會阻礙及時診斷和治療，尤其是在醫療資源匱乏的地區和醫療保險覆蓋範圍有限的人群中，最終減緩罕見疾病基因檢測解決方案的普及。

全球罕見疾病基因檢測市場趨勢

全球罕見疾病基因檢測市場正經歷一場變革，而人工智慧驅動的變異解讀技術的進步是推動這項變革的主要動力。機器學習和自然語言處理技術的融合提高了變異分類的準確性和可重複性，有效解決了長期存在的解讀難題。透過整合文獻資料、表現型相關性以及對特定族群變異的洞察，檢測實驗室能夠簡化流程，產生高效的報告，並專注於具有影響力的結果。這一趨勢不僅縮短了檢測結果的報告時間，還實現了臨床決策支援的標準化，並促進了分散式檢測環境的高效運作。因此，市場正朝著更複雜、數據驅動的解決方案發展，以應對罕見疾病的複雜性。

目錄

介紹

  • 調查目的
  • 市場定義和範圍

調查方法

  • 研究過程
  • 二級資料和一級資料的方法
  • 市場規模估算方法

執行摘要

  • 全球市場展望
  • 市場主要亮點
  • 細分市場概覽
  • 競爭環境概述

市場動態及展望

  • 總體經濟指標
  • 促進者和機會
  • 抑制因素和挑戰
  • 供給面趨勢
  • 需求面趨勢
  • 波特的分析和影響

關鍵市場分析

  • 關鍵成功因素
  • 影響市場的因素
  • 主要投資機會
  • 生態系測繪
  • 2025年市場魅力指數
  • PESTLE分析
  • 監理情勢

全球罕見疾病基因檢測市場規模：依檢測類型分類

  • 全EXOME定序（WES）
  • 全基因組定序（WGS）
  • 基因檢測
  • 染色體微陣列

全球罕見疾病基因檢測市場規模：依疾病類別分類

  • 代謝性疾病
  • 神經肌肉疾病
  • 染色體異常
  • 結締組織疾病

全球罕見疾病基因檢測市場規模：依最終用戶分類

  • 醫院
  • 參考實驗室
  • 研究機構

全球罕見疾病基因檢測市場規模：依分銷管道分類

  • 直接向醫生銷售
  • 面向一般消費者

全球罕見疾病基因檢測市場規模：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太國家
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲國家
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

競爭資訊

  • 前五大公司對比
  • 主要公司2025年的市場定位
  • 主要市場公司採取的策略
  • 近期市場趨勢
  • 企業市場占有率分析，2025 年
  • 主要公司的完整公司簡介
    • 公司詳情
    • 產品系列分析
    • 按細分市場進行企業市佔率分析
    • 銷售收入年比比較（2023-2025 年）

主要公司簡介

  • Illumina Inc.
  • Invitae Corporation
  • GeneDx（OPKO Health）
  • Blueprint Genetics
  • Centogene AG
  • Fulgent Genetics
  • PreventionGenetics
  • Ambry Genetics
  • LabCorp
  • Quest Diagnostics
  • Baylor Genetics
  • Greenwood Genetic Center
  • University of Chicago Genetics
  • Pacific Biosciences
  • Oxford Nanopore Technologies

結論與建議

簡介目錄
Product Code: SQMIG35J2287

Global Rare Disease Genetic Testing Market size was valued at USD 4.52 Billion in 2024 and is poised to grow from USD 5.08 Billion in 2025 to USD 12.85 Billion by 2033, growing at a CAGR of 12.32% during the forecast period (2026-2033).

The market for global rare disease genetic testing is being propelled by the increasing adoption of next-generation sequencing technologies and heightened awareness of the importance of early disease diagnosis. Support from government initiatives and the growth of precision medicine are also significant factors fuelling this demand, alongside the rising preference for personalized healthcare. Moreover, expansions in genomic and newborn screening programs, coupled with ongoing investments in advanced sequencing technology and bioinformatics, enhance the capacity for variant identification and interpretation. However, challenges such as high testing costs, a shortage of trained genetic counselors, ethical dilemmas concerning data privacy, and inconsistent reimbursement policies may hinder the long-term growth of the market for rare disease genetic testing.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rare Disease Genetic Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rare Disease Genetic Testing Market Segments Analysis

Global rare disease genetic testing market is segmented by test type, disease category, end-user, distributionchannel,and region. Based on test type, the market is segmented into Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), Gene PanelTesting,and Chromosomal Microarray. Based on disease category, the market is segmented into metabolic disorders, neuromuscular disorders, chromosomaldisorders,and connective tissue disorders. Based on end-user, the market is segmented into hospitals, reference laboratories,and research institutes. Based on distribution, the market is segmented into direct to physician and direct to consumer. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America,andtheMiddle East & Africa.

Driver of the Global Rare Disease Genetic Testing Market

One of the key market drivers for the global rare disease genetic testing market is the increasing prevalence and awareness of rare genetic disorders. As more individuals are diagnosed with these conditions, there is a growing demand for accurate and efficient testing methods. Advancements in genetic technology and research have led to the development of innovative testing solutions, enabling earlier detection and personalized treatment plans. Furthermore, supportive policies and initiatives from governments and healthcare organizations aimed at improving diagnostic capabilities for rare diseases are propelling market growth, ensuring that patients receive timely and effective care for their unique genetic challenges.

Restraints in the Global Rare Disease Genetic Testing Market

One significant restraint affecting the Global Rare Disease Genetic Testing Market is the high cost associated with genetic testing procedures and subsequent analysis. Many advanced genetic tests can be prohibitively expensive for patients and healthcare systems, limiting access to these crucial diagnostics. Additionally, the complexity of genetic materials and the need for specialized laboratories can lead to further financial burdens. This economic barrier can hinder timely diagnosis and treatment, particularly in underserved regions or among populations with limited insurance coverage, ultimately slowing the adoption of genetic testing solutions for rare diseases.

Market Trends of the Global Rare Disease Genetic Testing Market

The Global Rare Disease Genetic Testing market is witnessing a transformative shift driven by advancements in AI-driven variant interpretation. The integration of machine learning and natural language processing technologies is enhancing the precision and reproducibility of variant classifications, thus addressing longstanding interpretation challenges. By combining literature data, phenotype correlations, and population-specific variant knowledge, laboratories can streamline their processes, focusing on impactful results while generating efficient reports. This trend not only enhances turnaround times but also standardizes clinical decision support, promoting effective operations across distributed testing environments. As a result, the market is evolving towards more sophisticated, data-driven solutions tailored to the complexities of rare diseases.

Table of Contents

Introduction

  • Objectives of the Study
  • Market Definition & Scope

Research Methodology

  • Research Process
  • Secondary & Primary Data Methods
  • Market Size Estimation Methods

Executive Summary

  • Global Market Outlook
  • Key Market Highlights
  • Segmental Overview
  • Competition Overview

Market Dynamics & Outlook

  • Macro-Economic Indicators
  • Drivers & Opportunities
  • Restraints & Challenges
  • Supply Side Trends
  • Demand Side Trends
  • Porters Analysis & Impact
    • Competitive Rivalry
    • Threat of Substitute
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors
  • Market Impacting Factors
  • Top Investment Pockets
  • Ecosystem Mapping
  • Market Attractiveness Index 2025
  • PESTEL Analysis
  • Regulatory Landscape

Global Rare Disease Genetic Testing Market Size by Test Type & CAGR (2026-2033)

  • Market Overview
  • Whole Exome Sequencing (WES)
  • Whole Genome Sequencing (WGS)
  • Gene Panel Testing
  • Chromosomal Microarray

Global Rare Disease Genetic Testing Market Size by Disease Category & CAGR (2026-2033)

  • Market Overview
  • Metabolic Disorders
  • Neuromuscular Disorders
  • Chromosomal Disorders
  • Connective Tissue Disorders

Global Rare Disease Genetic Testing Market Size by End-User & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Reference Laboratories
  • Research Institutes

Global Rare Disease Genetic Testing Market Size by Distribution & CAGR (2026-2033)

  • Market Overview
  • Direct to Physician
  • Direct to Consumer

Global Rare Disease Genetic Testing Market Size & CAGR (2026-2033)

  • North America (Test Type, Disease Category, End-User, Distribution)
    • US
    • Canada
  • Europe (Test Type, Disease Category, End-User, Distribution)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Test Type, Disease Category, End-User, Distribution)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Test Type, Disease Category, End-User, Distribution)
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Test Type, Disease Category, End-User, Distribution)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Illumina Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Invitae Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GeneDx (OPKO Health)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Blueprint Genetics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Centogene AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fulgent Genetics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PreventionGenetics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ambry Genetics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • LabCorp
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Quest Diagnostics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baylor Genetics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Greenwood Genetic Center
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • University of Chicago Genetics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pacific Biosciences
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Oxford Nanopore Technologies
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations